PANews reported on September 20th that Faraday Future announced a strategic investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) through a private equity (PIPE) transaction, with the intention of launching cryptocurrency and Web3-related businesses. Following the completion of the necessary shareholder approval process, QLGN is expected to change its name to CXC10 and focus on its three growth engines: cryptocurrency and Web3 ecosystem development. The PIPE financing round was led by Faraday Future and its founder and global co-CEO, Jia Yueting, with participation from blockchain technology company SIGN Foundation. FF President Wang Jianjun also participated in the round. Faraday Future has agreed to invest approximately $30 million in QLGN at an effective price of $2.246 per share, subject to closing conditions, representing approximately 55% of QLGN's outstanding common stock. In addition, Jia Yueting plans to personally invest approximately $4 million, representing approximately 7% of QLGN's common stock. Jia Yueting has also agreed to a voluntary two-year lock-up period on his personal investment. Upon completion of the transaction, Jia Yueting will serve as QLGN's Chief Advisor, Wang Jianjun will be appointed Co-CEO of QLGN, and FF CFO Koti Meka will be appointed CFO.PANews reported on September 20th that Faraday Future announced a strategic investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) through a private equity (PIPE) transaction, with the intention of launching cryptocurrency and Web3-related businesses. Following the completion of the necessary shareholder approval process, QLGN is expected to change its name to CXC10 and focus on its three growth engines: cryptocurrency and Web3 ecosystem development. The PIPE financing round was led by Faraday Future and its founder and global co-CEO, Jia Yueting, with participation from blockchain technology company SIGN Foundation. FF President Wang Jianjun also participated in the round. Faraday Future has agreed to invest approximately $30 million in QLGN at an effective price of $2.246 per share, subject to closing conditions, representing approximately 55% of QLGN's outstanding common stock. In addition, Jia Yueting plans to personally invest approximately $4 million, representing approximately 7% of QLGN's common stock. Jia Yueting has also agreed to a voluntary two-year lock-up period on his personal investment. Upon completion of the transaction, Jia Yueting will serve as QLGN's Chief Advisor, Wang Jianjun will be appointed Co-CEO of QLGN, and FF CFO Koti Meka will be appointed CFO.

Faraday Future to Invest $41 Million in Qualigen via PIPE for Cryptocurrency Business

2025/09/20 09:13

PANews reported on September 20th that Faraday Future announced a strategic investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) through a private equity (PIPE) transaction, with the intention of launching cryptocurrency and Web3-related businesses. Following the completion of the necessary shareholder approval process, QLGN is expected to change its name to CXC10 and focus on its three growth engines: cryptocurrency and Web3 ecosystem development. The PIPE financing round was led by Faraday Future and its founder and global co-CEO, Jia Yueting, with participation from blockchain technology company SIGN Foundation. FF President Wang Jianjun also participated in the round.

Faraday Future has agreed to invest approximately $30 million in QLGN at an effective price of $2.246 per share, subject to closing conditions, representing approximately 55% of QLGN's outstanding common stock. In addition, Jia Yueting plans to personally invest approximately $4 million, representing approximately 7% of QLGN's common stock. Jia Yueting has also agreed to a voluntary two-year lock-up period on his personal investment. Upon completion of the transaction, Jia Yueting will serve as QLGN's Chief Advisor, Wang Jianjun will be appointed Co-CEO of QLGN, and FF CFO Koti Meka will be appointed CFO.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights